Emerging clinical relevance of microbiome in cancer:promising biomarkers and therapeutic targets  

作　　者：Jia-Hao Dai Xi-Rong Tan Han Qiao Na Liu 

机构地区：[1]State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510050,China

出　　处：《Protein & Cell》2024年第4期239-260,共22页蛋白质与细胞（英文版）

基　　金：supported by grants from the Guangzhou Science and Technology Project(202206010013 to N.Liu);the Guangdong Basic and Applied Basic Research Foundation(2022A1515220010 to N.Liu);the Fundamental Research Funds for the Central Universities,Sun Yat-sen University(22yklj07 to N.Liu).

摘　　要：The profound influence of microbiota in cancer initiation and progression has been under the spotlight for years,leading to numerous researches on cancer microbiome entering clinical evaluation.As promising biomarkers and therapeutic targets,the critical involvement of microbiota in cancer clinical practice has been increasingly appreciated.Here,recent progress in this field is reviewed.We describe the potential of tumor-associated microbiota as effective diagnostic and prognostic biomarkers,respectively.In addition,we highlight the relationship between microbiota and the therapeutic efficacy,toxicity,or side effects of commonly utilized treatments for cancer,including chemotherapy,radiotherapy,and immunotherapy.Given that microbial factors influence the cancer treatment outcome,we further summarize some dominating microbial interventions and discuss the hidden risks of these strategies.This review aims to provide an overview of the applications and advancements of microbes in cancer clinical relevance.

关 键 词：MICROBIOME CANCER DIAGNOSIS PROGNOSIS THERAPY 

分 类 号：R730.5[医药卫生—肿瘤]